title: MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy.
abstract: This study was aimed to investigate the potential role of microRNA-29c (miR-29c) in regulating the sensitivities of nasopharyngeal carcinoma (NPC) to ionizing radiation (IR) and cisplatin. Low expression of miR-29c was positively associated with therapeutic resistance in 159 NPC cases. Our further in vitro and in vivo studies illustrated ectopic restoration of miR-29c substantially enhanced the sensitivity of NPC cells to IR and cisplatin treatment by promoting apoptosis. Furthermore, we detected miR-29c repressed expression of anti-apoptotic factors, Mcl-1 and Bcl-2 in NPC tissues and cell lines. These data indicate miR-29c might serve as a potential therapeutic sensitizer in NPC treatment.
authors.affiliation: State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.
authors.forename: Jia-Xing
authors.initials: JX
authors.lastname: Zhang
authors.forename: Dong
authors.initials: D
authors.lastname: Qian
authors.forename: Feng-Wei
authors.initials: FW
authors.lastname: Wang
authors.forename: Ding-Zhun
authors.initials: DZ
authors.lastname: Liao
authors.forename: Jin-Huan
authors.initials: JH
authors.lastname: Wei
authors.forename: Zhu-Ting
authors.initials: ZT
authors.lastname: Tong
authors.forename: Jia
authors.initials: J
authors.lastname: Fu
authors.forename: Xiao-Xia
authors.initials: XX
authors.lastname: Huang
authors.forename: Yi-Ji
authors.initials: YJ
authors.lastname: Liao
authors.forename: Hai-Xia
authors.initials: HX
authors.lastname: Deng
authors.forename: Yi-Xin
authors.initials: YX
authors.lastname: Zeng
authors.forename: Dan
authors.initials: D
authors.lastname: Xie
authors.forename: Shi-Juan
authors.initials: SJ
authors.lastname: Mai
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics / Q000528:radiation effects; D002277:Carcinoma; D002945:Cisplatin / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D008297:Male; D051379:Mice; D035683:MicroRNAs / Q000235:genetics*; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000532:radiotherapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics; D011839:Radiation, Ionizing; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C532045:MIRN29a microRNA, human; C579094:Mcl1 protein, mouse; D035683:MicroRNAs; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D019253:Proto-Oncogene Proteins c-bcl-2; D002945:Cisplatin